ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $23.4M of Roivant Sciences Ltd.
Sold$23,382,600
$11.79Price
1,983,257Shares
−10%Stake
What ROIV did after the filing
- The stock from Wed, Sep 25 open, $11.63
- +1.0%
- S&P 500, same days
- +3.5%
Measured over 30 trading days, to the Nov 6 close.
Traded Mon, Sep 23. Filed Tue, Sep 24, 9:01 PM ET, after the close. Returns use the Sep 25 open and the Nov 6 close. Not investment advice.